Dapagold 10 Tablet 15

Dapagold 10 Tablet is used to manage type 2 diabetes by effectively lowering blood glucose levels, while also playing a role in protecting the heart and kidneys from long-term damage caused by prolonged high blood sugar.

Uses of Dapagold 10 Tablet are:

• Type 2 Diabetes: Lowers blood glucose levels effectively.
• Heart Protection: Helps protect the heart from long-term damage linked to diabetes.
• Kidney Protection: Helps protect kidney function from complications of prolonged high blood sugar.

• Swallow the tablet whole with a glass of water.
• Do not split, crush, or chew the tablet.
• The medicine can be taken with or without food, as prescribed by the doctor.
• Try to take the medicine at approximately the same time each day.

Dapagold 10 Tablet 15 is taken orally.

Dapagold 10 Tablet 15 contains dapagliflozin (10 mg), which works in the following ways:

• SGLT2 Inhibition: It blocks a protein called SGLT2 in your kidneys. This protein usually helps your kidneys reabsorb glucose from your urine back into your blood.
• Reduction of Blood Sugar Levels: By inhibiting SGLT2, dapagliflozin prevents glucose reabsorption, causing it to be flushed out from the body through urine. This process effectively lowers blood sugar levels.
• Mild Diuresis and Caloric Loss: As dapagliflozin increases urinary glucose excretion, it also leads to a slight increase in urination (mild diuresis) and caloric loss, which may assist with weight management.

• Store Dapagold 10 Tablet 15 at a temperature below 30°C.
• Place the medicine away from direct light.
• Keep out of reach of children to prevent accidental ingestion.

• Maintain a balanced diet with controlled sugar intake. This helps manage blood sugar levels effectively, enhancing the work of Dapagold 10 Tablet 15 in managing type 2 diabetes.
• Regular physical exercise, such as brisk walking or yoga, can help control blood glucose levels and contribute to cardiovascular health. This is especially beneficial since Dapagold 10 Tablet 15 also helps reduce the risk of heart-related hospitalisations.